Obesity Drugs Meet Platforms

Amazon and Eli Lilly are turning obesity treatment into a platform business, with care, prescribing, fulfillment and follow-up increasingly bundled into one flow. (aboutamazon.com) Amazon said April 23 that its new One Medical weight management program combines primary care, virtual follow-ups and Amazon Pharmacy pricing for glucagon-like peptide-1 drugs, the class that includes Wegovy, Zepbound and Lilly’s new pill Foundayo. The program says patients can start with structured consultations, regular monitoring and evidence-based protocols, while people with existing prescriptions can request 24/7 renewals starting at $29. (aboutamazon.com, health.amazon.com) One Medical’s program page says medication is prescribed only after a clinician review, accepts insurance and cash pay, and sends prescriptions to a patient’s preferred pharmacy, with Amazon Pharmacy pitched for free delivery and Prime pricing. The page lists both injectable drugs and pills, including semaglutide, tirzepatide and orforglipron, the generic name for Foundayo. (health.amazon.com) A glucagon-like peptide-1 drug works by making people feel full longer and reducing appetite, and Amazon is selling that treatment inside a primary-care subscription and pharmacy network rather than as a stand-alone prescription. Amazon bought One Medical in February 2023 and has since added same-day medication delivery, pharmacy coupon tools and an artificial-intelligence health assistant to its health business. (health.amazon.com, aboutamazon.com, aboutamazon.com, aboutamazon.com) Lilly is building a parallel stack. The Food and Drug Administration approved Foundayo on April 1 for adults with obesity, or overweight adults with at least one weight-related condition, and Lilly said prescriptions would be accepted immediately through LillyDirect, with shipping starting April 6 and broader retail availability after that. (fda.gov, lilly.com) Foundayo is a once-daily tablet, not an injection, and Lilly says it can be taken any time of day without food or water restrictions. In Lilly’s ATTAIN-1 trial, adults who stayed on the highest dose lost an average of 27.3 pounds, or 12.4% of body weight, versus 2.2 pounds on placebo. (lilly.com, pharmexec.com) The approval also showed how fast distribution is becoming part of the sales pitch. Lilly said Foundayo became available in the U.S. on April 9 through LillyDirect and telehealth providers, with retail pharmacy distribution beginning the same day, and listed starting prices of $25 a month for eligible commercially insured patients and $149 a month for self-pay. (lilly.com) The Food and Drug Administration said Foundayo was cleared 50 days after filing under the Commissioner’s National Priority Voucher pilot, 294 days ahead of its January 20, 2027 user-fee deadline. The agency called it the fastest approval of a new molecular entity since 2002. (fda.gov) Amazon and Lilly are also intersecting directly. Amazon Pharmacy said in March that it works with digital health companies including LillyDirect, WeightWatchers, UpScriptHealth and Noom, and has delivered GLP-1 medications since 2021. (aboutamazon.com) The result is that obesity drugs are no longer moving only through a doctor’s office and a neighborhood pharmacy. They are increasingly moving through branded care pathways where the same company can handle the screening, the prescription, the payment step and the box at the door. (aboutamazon.com, lilly.com, aboutamazon.com)